KRONUS TSH RECEPTOR AUTOANTIBODY (TRAB) ELISA ASSAY KIT
K080159 · Kronus Market Development Associates, Inc. · JZO · May 22, 2008 · Immunology
Device Facts
| Record ID | K080159 |
| Device Name | KRONUS TSH RECEPTOR AUTOANTIBODY (TRAB) ELISA ASSAY KIT |
| Applicant | Kronus Market Development Associates, Inc. |
| Product Code | JZO · Immunology |
| Decision Date | May 22, 2008 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.5870 |
| Device Class | Class 2 |
Intended Use
The KRONUS TRAb ELISA Assay Kit is for the semi-quantitative determination of antibodies to the thyroid stimulating hormone receptor in human serum. The KRONUS TRAb ELISA Assay is useful as an aid in the diagnosis of Graves' Disease in conjunction with other clinical and laboratory findings.
Device Story
KRONUS TRAb ELISA Assay Kit is an in vitro diagnostic test for human serum samples. It utilizes enzyme-linked immunosorbent assay (ELISA) technology to detect TSH receptor autoantibodies. The assay is performed in a clinical laboratory setting by trained personnel. The device provides semi-quantitative results, which are interpreted by clinicians alongside patient history and other laboratory data to assist in diagnosing Graves' Disease. The test aids in clinical decision-making by identifying the presence of autoantibodies associated with thyroid dysfunction.
Clinical Evidence
No clinical data provided in the document; bench testing only.
Technological Characteristics
ELISA-based immunological test system. Analyte: TSH receptor autoantibodies. Sample type: human serum. Methodology: enzyme-linked immunosorbent assay. Classification: Class II, 21 CFR 866.5870, Product Code JZO.
Indications for Use
Indicated for semi-quantitative determination of TSH receptor antibodies in human serum as an aid in the diagnosis of Graves' Disease in conjunction with other clinical and laboratory findings.
Regulatory Classification
Identification
A thyroid autoantibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the thyroid autoantibodies (antibodies produced against the body's own tissues). Measurement of thyroid autoantibodies may aid in the diagnosis of certain thyroid disorders, such as Hashimoto's disease (chronic lymphocytic thyroiditis), nontoxic goiter (enlargement of thyroid gland), Grave's disease (enlargement of the thyroid gland with protrusion of the eyeballs), and cancer of the thyroid.
Related Devices
- K032134 — TSH RECEPTOR ANTIBODY (TRAB) COATED TUBE (CT) ASSAY KIT · Kronus Market Development Associates, Inc. · Sep 10, 2003
- K033454 — BRAHMS DIAGNOSTICA LUMITEST TRAK HUMAN · Brahms Diagnostica, LLC · Mar 22, 2004
- K984165 — ANTI-THYROGLOBULIN EIA DIAGNOSTIC TEST KIT · The Binding Site, Ltd. · Feb 2, 1999
- K080092 — ELECSYS ANTI-TSHR IMMUNOASSAY, ELECSYS PRECICONTROL THYROAB · Roche Diagnostics Corp. · Jul 28, 2008
- K981857 — QUANTA LITE TPO ELISA · Inova Diagnostics, Inc. · Jul 29, 1998
Submission Summary (Full Text)
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract image of an eagle.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 2 2 2008
KRONUS Market Development Associates, Inc. c/o Ms. Heather Viele Director of Technical Affairs 12554 West Bridger Street Suite 108 Boise, ID 83713
Re: k080159
Trade/Device Name: KRONUS TSH Receptor Autoantibody (TRAb) ELISA Kit Regulation Number: 21 CFR 866.5870 Regulation Name: Thyroid autoantibody immunological test system Regulatory Class: Class II Product Code: JZO Dated: April 17, 2008 Received: April 18, 2008
Dear Ms. Viele:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The
{1}------------------------------------------------
Page 2 -
FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Robert L. Becker
Robert L. Becker, Jr., M.D., Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## Indications for Use
510(k) Number (if known): Fobe assigned by FDA KO 8 2 15 9
Device Name:
KRONUS TSH Receptor Antibody (TRAb) ELISA Assay Kit
Indications for Use Statement:
The KRONUS TRAb ELISA Assay Kit is for the semi-quantitative determination of antibodies to the thyroid stimulating hormone receptor in human serum. The KRONUS TRAb ELISA Assay is useful as an aid in the diagnosis of Graves' Disease in conjunction with other clinical and laboratory findings.
(Please Do Not Write Below This Line - Continue On another Page If Needed)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use X (Pursuant to 21 CFR 801.109)
OR
Over-the-counter Use
Mana M Chan
Division Sign Off
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) k080159